Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 4/20 | 0.35 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | Q9HBH1 | 1/20 | 0.33 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25070897 | 0.93 | FURIN (0.44) | CPB2NMT2NMT1FURINPCSK6 | |
| SCHEMBL24454145 | 0.87 | NMT2 (0.34) | CPB2NMT2NMT1SIRT6SIRT1 | |
| SCHEMBL21515141 | 0.86 | NMT2 (0.36) | CPB2NMT2NMT1SIRT6SIRT1 | |
| SCHEMBL23682487 | 0.86 | NMT2 (0.36) | CPB2NMT2NMT1SIRT6SIRT1 | |
| SCHEMBL25070702 | 0.85 | NMT2 (0.38) | CPB2NMT2NMT1SIRT6SIRT1 | |
| SCHEMBL25748774 | 0.85 | CPB2 (0.44) | CPB2NMT2NMT1SIRT6SIRT1 | |
| SCHEMBL27347114 | 0.85 | CPB2 (0.39) | CPB2NMT2NMT1SIRT6SIRT1 | |
| SCHEMBL22068068 | 0.83 | FURIN (0.32) | FURIN | |
| SCHEMBL18594688 | 0.83 | FURIN (0.32) | FURIN | |
| SCHEMBL24453626 | 0.82 | FURIN (0.41) | CPB2NMT2NMT1SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357864-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20190321483-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357864-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | BCR, ABL1, CD47 | CPB2 2686/4885NMT2 1188/4885NMT1 950/4885 |
| US-20190321483-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | BCR, ABL1, CD47 | CPB2 2686/4885NMT2 1188/4885NMT1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.